Ich möchte Stephan Soyka von Solvay Seiyaku und Reiko Masuda von Bayer Yakuhin für hilfreiche Kommentare danken.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Alexander DL, Flynn JE, Linkins LA (1995) Innovation, R&D Productivity, and Global Market Share in the Pharmaceutical Industry. Review of Industrial Organization 10: 197–207
Akaho E, Fuji M, Inoue K, Hosono K, Bernan P, Gudorf P, Huang XJ (1995) A Comparative Study of Pricing and Marketing of Drugs Acting on the Central Nervous System in the U.S., Japan, and Quebec, with a Search for Factors to Stimulate Research and Development Activities. Journal of Research in Pharmaceutical Economics 6(4): 29–55
Chabala JC (1998) Historical Overview of the Developing Field of Molecular Diversity. In: Gordon EM, Kerwin JF Jr. (Hrsg) Combinatorial Chemistry and Molecular Diversity in Drug Discovery. New York, S 3–16
DiMasi JA, Hansen RW, Grabowski HG (2002) The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics 22: 151–185
EFPIA European Federation of Pharmaceutical Industries and Associations (2002) The European Pharmaceutical Industry-Key Data. Brüssel
FDA Federal Food and Drug Administration (2004) NCE approved 1998–2004. Http://www.fda.org (Zugriff am 01.10.2004)
Gambardella A, Orsenigo L, Pamolli F (2000) Global Competetiveness in Pharmaceuticals. Europäische Kommission, Brüssel
Grabowski H, Vernon J, DiMasi J (2003) Returns on Research and Development for 1990’s New Drug Introductions. PharmacoEconomics 20(3): 11–29
Granstrand O (1999) Internationalization of Corporate R&D: A Study of Japanese and Swedish Corporations. Research Policy 28: 275–302
Halliday RG (1996) Success in Pharmaceutical R&D: The Different Strategies of Western and Japanese Companies. Drug Information Journal 30: 821–838
Hawkins ES, Reich MR (1992) Japanese-Originated Pharmaceutical Products in the United States from 1960 to 1989: An Assessment of Innovation. Clinical Pharmacology & Therapeutics 51(1): 1–11
Henderson R, Cockburn I (1996) Scale, Scope and Spillovers: The Determinants of Research and Productivity in the Drug Industry. RAND Journal of Economics 27: 32–59
Hisashige A (1997) Healthcare Technology Assessment and the Challenge to Pharmaeconomics in Japan. PharmacoEconomics 11(4): 319–333
Huttin C (1995) The Japanese Drug Price Policy: A New Dynamic of Price Competition. Journal of Research in Pharmaceutical Economics 6(2): 21–34
Ikeda S, Ikegami N, Gudorf P, Olivier AJ, Ikeda M (1996) A Case for the Adoption of Pharmacoeconomic Guidelines in Japan. PharmacoEconomics 10(6): 546–551
Ikegami N, Mitchell W, Penner-Hahn J (1994) Pharmaceutical Prices, Quantities and Innovation. PharmacoEconomics 6(5): 424–433
IMS Health (2001) Pharma-Prognosis International, 2001–2005. Fairfield
JPA Japan Pharmaceutical Association (2004) Annual Report. TŌkyŌ
JETRO (1992) Your Market in Japan — Pharmaceuticals. Tokio (3. Aufl.)
JPMA Japan Pharmaceutical Manufacturers Association (2002) Pharmaceutical Administration and Regulations in Japan. Tokio
JPMA (2003) Data Book 2002. Tokio
Kiba T (1996) A Study of the Performance of the Japanese Companies’ Overseas-based R&D. NISTEP Report 43
Kiba T, Collison S (1998) R&D Performance in Japanese Companies: A Relative Evaluation of Overseas-Based and Domestic R&D. Science and Public Policy 25(4): 227–238
Kneller R (2003) Autarkic Drug Discovery in Japanese Pharmaceutical Companies: Insights into National Differences in Industrial Innovation. Research Policy 32: 1805–1827
Lahana R (1997) Virtuelle kombinatorsiche Chemie. Spektrum der Wissenschaft 6: 35–37
Mahlich J (2002) Probleme und Perspektiven der japanischen Pharmaindustrie. In: Pohl M, Wieczorek I (Hrsg) Japan 2001/2002 — Politik und Wirtschaft. Deutsches Institut für Asienkunde, Hamburg, S 184–208
Mahlich J (2003) Das japanische Innovationssystem im Überblick. In: Pohl M, Wieczorek I (Hrsg) Japan 2003 — Politik und Wirtschaft. Deutsches Institut für Asienkunde, Hamburg, S 193–221
Mahlich J (2004) Neue Entwicklungen in den Banken-Firmen Beziehungen in Japan. In: Pohl M, Wieczorek I (Hrsg) Japan 2004 — Politik und Wirtschaft. Deutsches Institut für Asienkunde, Hamburg, S 243–264
McLellan M (1997) A turning point in Japanese sales promotion. Scrip Magazine 10: 25–27
MHLW Ministry of Health, Labor and Welfare (2002) To Reinforce the Global Competitiveness of the Pharmaceutical Industry, Mainstay of the “Century of Life”—Vision of the Industry. Tokio
MOF Ministry of Finance (2005) Budget Program by Function. Tokio
Morgan Stanley Dean Witter (1998) Japan Investment Research: Japan Pharmaceuticals. Tokio
Morioka J (2004) An Overview of the US Drug Development Strategies of Japanese Pharmaceutical Companies. Business Briefing: PharmaTech 6: 1–6
Odagiri H, Yamawaki H (1986) A Study of Company Profit Rates Time Series — Japan and the United States. International Journal of Industrial Organization 4: 1–23
Ohmichi H (1994) Current Pharmacoeconomic Issues in Japanese Healthcare. PharmacoEconomics 6(3): 193–195
OECD (2004) Health Data. Paris
Okada Y, Kawara A (2004) Research Productivity in the Japanese Pharmaceutical Industry-Economies of Scale, Economies of Scope and Spillovers. Hitosubashi University, Working Paper
PhRMA Pharmaceutical Research and Manufacturers of America (1999) 1998 Industry Profile. Washington DC
PhRMA (2004) 2003 Industry Profile. Washington DC
Sharp M, Patel P, Pavitt K (1996) Europe’s Pharmaceutical Industry: An Innovation Profile. EIMS 32
Seo T (1994) Prescribing and Dispensing of Pharmaceuticals in Japan. PharmacoEconomics 6(2): 95–102
Sigurdson J (1996) Future Advantage Japan? London
Thomas LG (1994) Pricing, Regulation, and Competitiveness: Lessons for the US from the Japanese Pharmaceutical Industry. PharmacoEconomics 6(Suppl. 1): 67–70
Thomas LG (2001) The Japanese pharmaceutical industry: The new drug lag and the failure of industrial policy. Cheltenham
VFA Verband forschender Arzneimittelhersteller (2003) Die Arzneimittelindustrie in Deutschland. Berlin
Wood Mackenzie (2004) PharmaQuant® Plus Overview. Edinburgh
Yamamoto Y (1997) Ministry continues drug price cuts; foreign firms make in-roads. Japan Economic Almanac: 98–99
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mahlich, J. (2007). Die japanische Pharmaindustrie. In: Moerke, A., Walke, A. (eds) Japans Zukunftsindustrien. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-29808-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-540-29808-3_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-29806-9
Online ISBN: 978-3-540-29808-3
eBook Packages: Business and Economics (German Language)